Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HCP1904-2 in Essential Hypertension
NCT04830449Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of losartan, chlorthalidone in essential hypertension, sponsored by Hanmi Pharmaceutical. Started Oct 2020; status: completed.
02
Drugs
losartanchlorthalidone
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT04830449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04830449.